MARKET

ANTH

ANTH

Anthera Pharmace
EXMKT

Real-time Quotes | Nasdaq Last Sale

0.0002
+0.0002
+19900.00%
Closed 16:00 05/24 EDT
OPEN
--
PREV CLOSE
0.0001
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.090
52 WEEK LOW
0.0000
MARKET CAP
5.24K
P/E (TTM)
-0.0001
1D
5D
1M
3M
1Y
5Y
Major US Indexes End Higher Monday
GuruFocus News · 11/08/2021 21:06
US Indexes Close With Mixed Returns Wednesday
GuruFocus News · 07/28/2021 19:37
No Data
Learn about the latest financial forecast of ANTH. Analyze the recent business situations of Anthera Pharmace through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ANTH stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
High3.000
Average3.000
Low3.000
Current 0.0002
EPS
Actual
Estimate
-0.86-0.64-0.41-0.19
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 26.18M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
1
10.00K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.06%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/Director
Paul Truex
President/Chief Executive Officer/Director
J. Craig Thompson
Senior Vice President - Finance/Senior Vice President/Chief Accounting Officer
May Liu
Independent Director
Brent Furse
Independent Director
Christopher Henney
Independent Director
Brian Mueller
Independent Director
Philip Sager
Independent Director
David Thompson
No Data
No Data
About ANTH
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Webull offers kinds of Anthera Pharmaceuticals Inc stock information, including EXMKT:ANTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANTH stock methods without spending real money on the virtual paper trading platform.